DNMT3A mutations are found in approximately 25% of patients with acute myeloid leukemia (AML) and close to 10% in patients with myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) (1–4). This evidence concerns the gene DNMT3A and myeloproliferative disorder.